Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

2025-07-07
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle. Building on the long-standing success and performance of the best-in-class anchor fixation strength of the Q-FIX Family versus competitive devices*, the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With propr

Wound Care Centers Market Report 2025-2030, with Profiles of Smith & Nephew, 3M, Molnlycke Health Care, ConvaTec, Coloplast, Medline, Integra LifeSciences, B. Braun, Cardinal Health, & Derma Sciences

2025-07-07
The Wound Care Centers Market presents opportunities through specialized care, digitization, and supply chain optimization. Key trends include adoption of advanced treatments, telehealth, real-time analytics, and strategic partnerships. Regional and tailored approaches are essential for leveraging these market dynamics. Wound Care Centers Market Wound Care Centers Market Dublin, July 07, 2025 (GLOBE NEWSWIRE) -- The "Wound Care Centers Market by Product Type, Application, End User, Distribution

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

2025-06-30
European equities traded in the US as American depositary receipts were modestly higher late Thursda

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

2025-06-29
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world’s oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew’s purpose of ‘Life Unlimited’ - making a difference in patients’ lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a h

SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System

2025-06-26
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.

SNN vs. GEHC: Which Stock Is the Better Value Option?

2025-06-25
SNN vs. GEHC: Which Stock Is the Better Value Option?

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

2025-06-25
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Smith+Nephew’s new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing’ to trauma surgeons repairing tibial fractures

2025-06-24
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and mi

Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

2025-06-23
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee. As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value. Ajay’s experi

Smith+Nephew Stock May Gain From Strategic Deal With Standard Health

2025-06-20
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.